Principal Financial Group Inc. Buys 47,921 Shares of Kenvue Inc. $KVUE

Principal Financial Group Inc. grew its stake in shares of Kenvue Inc. (NYSE:KVUE) by 2.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,128,437 shares of the company’s stock after buying an additional 47,921 shares during the quarter. Principal Financial Group Inc. owned 0.11% of Kenvue worth $36,716,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of KVUE. Arrowstreet Capital Limited Partnership bought a new position in shares of Kenvue during the second quarter valued at about $6,528,000. Jump Financial LLC grew its stake in shares of Kenvue by 210.6% in the second quarter. Jump Financial LLC now owns 54,823 shares of the company’s stock worth $1,147,000 after purchasing an additional 37,170 shares during the last quarter. AXA S.A. grew its stake in shares of Kenvue by 21.1% in the second quarter. AXA S.A. now owns 48,892 shares of the company’s stock worth $1,023,000 after purchasing an additional 8,524 shares during the last quarter. NewEdge Advisors LLC grew its stake in shares of Kenvue by 219.1% in the second quarter. NewEdge Advisors LLC now owns 97,481 shares of the company’s stock worth $2,040,000 after purchasing an additional 66,930 shares during the last quarter. Finally, The Manufacturers Life Insurance Company grew its stake in shares of Kenvue by 0.6% in the second quarter. The Manufacturers Life Insurance Company now owns 1,873,705 shares of the company’s stock worth $39,217,000 after purchasing an additional 10,885 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Kenvue Stock Performance

Shares of KVUE opened at $17.59 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.96 and a quick ratio of 0.68. Kenvue Inc. has a one year low of $14.02 and a one year high of $24.61. The company has a 50-day simple moving average of $17.65 and a two-hundred day simple moving average of $17.24. The firm has a market capitalization of $33.76 billion, a PE ratio of 20.69, a price-to-earnings-growth ratio of 3.99 and a beta of 0.55.

Kenvue (NYSE:KVUE) last issued its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping the consensus estimate of $0.27 by $0.05. Kenvue had a net margin of 10.61% and a return on equity of 20.76%. The business had revenue of $3.91 billion during the quarter, compared to analyst estimates of $3.84 billion. During the same period last year, the business posted $0.24 earnings per share. Kenvue’s quarterly revenue was up 4.5% compared to the same quarter last year. On average, analysts anticipate that Kenvue Inc. will post 1.16 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 27th. Shareholders of record on Wednesday, May 13th will be issued a $0.2075 dividend. The ex-dividend date is Wednesday, May 13th. This represents a $0.83 annualized dividend and a yield of 4.7%. Kenvue’s dividend payout ratio (DPR) is 107.79%.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on KVUE shares. Barclays cut their target price on Kenvue from $19.00 to $18.00 and set an “equal weight” rating on the stock in a research note on Tuesday, April 14th. Weiss Ratings raised Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Friday. UBS Group cut their target price on Kenvue from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 7th. Argus raised Kenvue to a “hold” rating in a research note on Friday, March 6th. Finally, Jefferies Financial Group cut Kenvue from a “buy” rating to a “hold” rating and cut their target price for the stock from $23.00 to $18.00 in a research note on Friday, January 30th. Three research analysts have rated the stock with a Buy rating and thirteen have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $19.33.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.